Patients with advanced-stage classic Hodgkin lymphoma had a longer progression-free survival rate with Opdivo plus AVD, a chemotherapy regimen, compared with Adcetris plus AVD.
Patients with non-small cell lung cancer who cleared 50% or more of cancerous DNA from their blood by their fourth treatment cycle tended to have better outcomes on maintenance therapy, research showed.
After a median follow-up of four years, the survival benefit, including progression-free survival persisted in patients with advanced clear cell renal cell carcinoma treated with Lenvima plus Keytruda compared with those treated with Sutent.